Allarity Therapeutics Files 8-K

Ticker: ALLR · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1860657

Sentiment: neutral

Topics: filing, financials, sec

TL;DR

ALLARITY THERAPEUTICS FILED AN 8-K, EXPECT MORE FINANCIALS SOON.

AI Summary

Allarity Therapeutics, Inc. filed an 8-K on March 14, 2025, reporting on events that occurred on March 13, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.

Why It Matters

This filing indicates a routine update or submission of financial information and exhibits by Allarity Therapeutics, Inc. to the SEC.

Risk Assessment

Risk Level: low — The filing appears to be a standard procedural update with no immediate negative or positive news impacting the company's operations or financial standing.

Key Numbers

Key Players & Entities

FAQ

What specific financial statements or exhibits were filed?

The filing indicates that financial statements and exhibits were submitted, but the specific details of these documents are not provided in the excerpt.

What is the purpose of this 8-K filing?

This 8-K filing is a current report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, primarily for reporting financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on March 13, 2025.

What is the principal executive office address for Allarity Therapeutics, Inc.?

The principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108.

Is there any information about recent material events in this filing?

Based on the provided text, the filing is categorized under 'Other Events' and 'Financial Statements and Exhibits', suggesting it's a procedural filing rather than reporting a specific material event.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 regarding Allarity Therapeutics, Inc. (ALLR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing